The manufacture of finished doses will commence in 2022 and at full operational capacity, the annual production is expected to exceed 100 million doses annually
In H1FY21, it attracted PE deals worth US $ 1.6 billion compared to US $ 3 billion in CY2020
New interim data from these studies demonstrate that a booster dose of the Johnson & Johnson Covid-19 vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after the primary single-dose vaccination.
The submission to the US FDA has been initiated and they intend to file these data with the European Medicines Agency and other regulatory bodies in the coming weeks
Domestic business was up 41.9% YoY and 27.7% QoQ
The aim is to give a fillip to R&D in the health sector to face the Covid-19 challenge
CRISIL Ratings has revised its outlook on the long term ratings of Krishna Institute Of Medical Sciences Limited (KIMS) to 'Positive' from 'Stable' while reaffirming the ratings at 'CRISIL AA-/CRISIL A1+'
The foundation has been working closely with the Kidwai Memorial Institute of Oncology on several projects since 2001
This year, the company plans to set up more than 200 labs and 3000 collection centres across the world and has ended FY 21 with a revenue of Rs 800 crores
BD worked with JCI to create a Gold Standard benchmarked safety program called Preventing Risks of Infections and Medication Errors in IV Therapy (PRIME)
Subscribe To Our Newsletter & Stay Updated
